DK1059931T3 - Anvendelse af CD137 til fremme af perifere monocytters proliferation - Google Patents

Anvendelse af CD137 til fremme af perifere monocytters proliferation

Info

Publication number
DK1059931T3
DK1059931T3 DK99910331T DK99910331T DK1059931T3 DK 1059931 T3 DK1059931 T3 DK 1059931T3 DK 99910331 T DK99910331 T DK 99910331T DK 99910331 T DK99910331 T DK 99910331T DK 1059931 T3 DK1059931 T3 DK 1059931T3
Authority
DK
Denmark
Prior art keywords
monocyte proliferation
promote peripheral
peripheral monocyte
proliferation
utilization
Prior art date
Application number
DK99910331T
Other languages
English (en)
Inventor
Joachim Langstein
Herbert Schwarz
Original Assignee
Merckle Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle Gmbh filed Critical Merckle Gmbh
Application granted granted Critical
Publication of DK1059931T3 publication Critical patent/DK1059931T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/40Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
DK99910331T 1998-07-15 1999-03-05 Anvendelse af CD137 til fremme af perifere monocytters proliferation DK1059931T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98103859 1998-07-15
PCT/EP1999/001440 WO1999044629A2 (de) 1998-03-05 1999-03-05 Verwendung von cd137 zur förderung der proliferation peripherer monocyten

Publications (1)

Publication Number Publication Date
DK1059931T3 true DK1059931T3 (da) 2003-03-24

Family

ID=8231533

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910331T DK1059931T3 (da) 1998-07-15 1999-03-05 Anvendelse af CD137 til fremme af perifere monocytters proliferation

Country Status (21)

Country Link
US (1) US6627200B1 (da)
EP (1) EP1059931B1 (da)
JP (1) JP2003521439A (da)
KR (1) KR20010041624A (da)
AT (1) ATE228371T1 (da)
AU (1) AU747063B2 (da)
BR (1) BR9908518A (da)
CA (1) CA2322684A1 (da)
CZ (1) CZ20003238A3 (da)
DE (1) DE59903541D1 (da)
DK (1) DK1059931T3 (da)
EE (1) EE200000510A (da)
ES (1) ES2188140T3 (da)
HU (1) HUP0102046A3 (da)
IS (1) IS1986B (da)
NO (1) NO20004393L (da)
NZ (1) NZ506695A (da)
PL (1) PL343427A1 (da)
PT (1) PT1059931E (da)
SI (1) SI1059931T1 (da)
WO (1) WO1999044629A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232896A1 (en) * 2001-10-04 2005-10-20 Herbert Schwarz Cd137 as a proliferation factor for hematopoietic stem cells
EP1545578A4 (en) * 2002-08-28 2010-07-07 Immunex Corp COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES
EP1575672A2 (en) * 2002-12-16 2005-09-21 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5861191B2 (ja) * 2010-09-30 2016-02-16 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
WO2014165452A1 (en) * 2013-04-03 2014-10-09 The Regents Of The University Of California Compositions and methods for inhibiting viral activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03145499A (ja) * 1989-10-31 1991-06-20 Nippon Kosei Butsushitsu Gakujiyutsu Kiyougikai ヒト単球成長因子
DE4222980A1 (de) 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
CA2429027C (en) * 1993-09-16 2011-04-05 Indiana University Foundation Antibodies against human receptor h4-1bb
CA2108401A1 (en) * 1993-09-27 1995-03-28 Martin Lotz Receptor induced by lymphocyte activation in imflammatory response

Also Published As

Publication number Publication date
IS1986B (is) 2005-02-15
BR9908518A (pt) 2000-11-21
HUP0102046A2 (hu) 2001-10-28
DE59903541D1 (de) 2003-01-09
CA2322684A1 (en) 1999-09-10
SI1059931T1 (en) 2003-04-30
PL343427A1 (en) 2001-08-13
EE200000510A (et) 2002-02-15
NO20004393D0 (no) 2000-09-04
WO1999044629A3 (de) 2000-01-06
KR20010041624A (ko) 2001-05-25
HUP0102046A3 (en) 2006-02-28
US6627200B1 (en) 2003-09-30
ATE228371T1 (de) 2002-12-15
PT1059931E (pt) 2003-04-30
AU747063B2 (en) 2002-05-09
NZ506695A (en) 2005-01-28
IS5613A (is) 2000-08-30
CZ20003238A3 (cs) 2001-10-17
EP1059931B1 (de) 2002-11-27
ES2188140T3 (es) 2003-06-16
AU2932499A (en) 1999-09-20
NO20004393L (no) 2000-10-31
EP1059931A2 (de) 2000-12-20
JP2003521439A (ja) 2003-07-15
WO1999044629A2 (de) 1999-09-10

Similar Documents

Publication Publication Date Title
DK0991619T3 (da) Inhibitorer af alfa 4-beta 1-medieret celleadhæsion
DE60014966D1 (de) Behandlung zur vermeidung von kalzifizierung für fixierte biomaterialien
ATE413386T1 (de) Ppar-gamma modulatoren
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DK0785948T3 (da) Analoger af keratinocyt vækstfaktor
PT1144365E (pt) Inibidores da adesao de celulas mediada por alfa4beta1
BR9813778A (pt) Utilização de pelo menos um fucano.
DE69811330D1 (de) Reinigungspflaster zur verbesserung des hautzustandes
DK1059931T3 (da) Anvendelse af CD137 til fremme af perifere monocytters proliferation
DE69938488D1 (de) Geschachteltes vorwärtsgekoppeltes System zur Reduzierung von Verzerrungen
DE69624918T2 (de) Verwendung von pseudopterosin zur förderung der wundheilung
PT989850E (pt) Utilizacao de pramipexole no tratamento da sindroma das pernas inquietas
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN
TR199801492A2 (xx) S�lfonamid-ikame etmi� bile�ikleri elde etme usulleri.
DE60000658T2 (de) Zusammensetzung zur behandlung von psoriasis
IT1316806B1 (it) Impianto di trattamento per substrati piatti
DE29614127U1 (de) Bandage zur Fixierung des Sprunggelenks